Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C round brings $45.9mm to Otonomy

Executive Summary

Otonomy Inc. (developing controlled-release drugs for inner ear conditions) raised $45.9mm through its Series C round. OrbiMed Advisors led (and takes a board seat) and was joined by new investors Aperture Venture Partners and Osage University Partners. Also participating were returning backers Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners, and TPG Biotech. Proceeds will fund upcoming Phase II trials of OTO104 for Ménière's disease and OTO201, an antibiotic for children with otitis media and effusion at the time of tympanostomy tube replacement surgery. Funds will also help propel preclinical candidates into trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies